Results 81 to 90 of about 9,281 (210)

Seronegative Neuromyelitis Optica Spectrum - The challenges on disease definition and pathogenesis

open access: yesArquivos de Neuro-Psiquiatria, 2014
Neuromyelitis optica spectrum disorders (NMOSD) are characterized by severe optic neuritis and/or longitudinally extensive transverse myelitis, and some brain lesions are also unique to NMOSD.
Douglas Kazutoshi Sato   +4 more
doaj   +1 more source

Metabolomic Profiling in Neuromyelitis Optica Spectrum Disorder Biomarker Discovery

open access: yesMetabolites, 2020
There is no specific test for diagnosing neuromyelitis optica spectrum disorder (NMOSD), a disabling autoimmune disease of the central nervous system. Instead, diagnosis relies on ruling out other related disorders with overlapping clinical symptoms.
Maxton E. Thoman, Susan C. McKarns
doaj   +1 more source

The immunological landscape of the area postrema in neuromyelitis optica spectrum disorders

open access: yesBrain Pathology, EarlyView.
Aquaporin‐4 antibody‐positive neuromyelitis spectrum disorder is characterized by large tissue destructive lesions in medulla, spinal cord, and optic nerves, with only partial recovery from clinical symptoms, and by lesions with very little tissue destruction and mostly complete recovery from clinical symptoms, as seen in the area postrema ...
Qian Yu   +11 more
wiley   +1 more source

IL-33 relieves nerve injury by mediating microglial polarization in neuromyelitis optica spectrum disorders via the IL-33/ST2 pathway

open access: yesIBRO Neuroscience Reports
Interleukin-33 (IL-33) is a member of the interleukin-1 cytokine family. Its function in regulating microglial M1/M2 polarization in neuromyelitis optica spectrum disorder (NMOSD) is still unelucidated.
Lu Huang   +3 more
doaj   +1 more source

Australian consensus recommendations for the management of increased meningococcal infection risk in adults with neurological diseases treated with complement inhibitors

open access: yesInternal Medicine Journal, EarlyView.
Abstract Complement inhibitor therapy carries a risk of serious infections, including meningococcal disease. Here we provide evidence‐based recommendations and expert consensus for immunisation and prophylactic treatment of patients receiving, or planning to receive, complement inhibitors for neurological conditions in the Australian setting.
Katherine A. Buzzard   +13 more
wiley   +1 more source

Different Exosomal microRNA Profile in Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorders

open access: yesFrontiers in Immunology, 2020
Neuromyelitis optica spectrum disorders (NMOSD) and multiple sclerosis (MS) are inflammatory demyelinating diseases of the central nervous system. Exosomal microRNAs (miRNAs) are emerging biomarkers for demyelinating diseases. In this study, 52 aquaporin-
Chen Chen   +15 more
doaj   +1 more source

Reframing the Gut–Brain Axis: The Gut Wall as a Neural Immune Interface in Multiple Sclerosis and Autoimmune Neurological Diseases

open access: yesAnnals of Neurology, Volume 100, Issue 5, Page 915-930, November 2026.
Gut wall physiology in multiple sclerosis (MS) and autoimmune neurologic diseases remains underexplored but may span gut barrier dysfunction, enteric glial targeting, mucosal immune dysregulation, and autoimmune targets within the enteric nervous system (ENS).
Federico Montini   +4 more
wiley   +1 more source

NMOSD acute attack: Understanding, treatment and innovative treatment prospect

open access: yes, 2020
Neuromyelitis optica spectrum disorder (NMOSD) is a group of severe inflammatory demyelinating disorders of the central nervous system that involves the optic nerve and spinal cord.
Kermode, A.G., Qiu, W., Hu, X., Ma, X.
core  

Neurodegenerative Diseases: Epidemiology, Risk Factors, Classification, Pathophysiology, Clinical Features, Diagnosis, and Therapeutic Strategies

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Neurodegenerative diseases share convergent risk architectures and pathological mechanisms, yet diverge in selective vulnerability, clinical presentation, and therapeutic responsiveness. This review integrates cross‐disease epidemiology, pathophysiology, diagnosis, and treatment, highlighting the transition from symptomatic care toward biomarker‐guided
Zimeng He   +4 more
wiley   +1 more source

Disconnected and overconnected nodes in NMOSD patients.

open access: yes, 2019
Cortical surface representation of the difference in mean global efficiency, clustering, and degree between patient and volunteer groups (in red significantly increased parameter in NMOSD patients compared with healthy subjects, and in blue significantly
Stéphane Kremer (303296)   +7 more
core   +1 more source

Home - About - Disclaimer - Privacy